← Eichor
Study identifier: NCT06295965 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Condition: Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma  ·  Sponsor: University of Washington

PhaseN/A
Planned participants2000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Swisher Lab Research Coordinators  ·  206-616-8927  ·  swisherlabrc@uw.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06295965